|1.||Klebanoff, Mark A: 2 articles (03/2015 - 01/2002)|
|2.||Wouters, Emiel F M: 2 articles (03/2010 - 09/2006)|
|3.||Geraets, Liesbeth: 2 articles (03/2010 - 09/2006)|
|4.||Bast, Aalt: 2 articles (03/2010 - 09/2006)|
|5.||Hageman, Geja J: 2 articles (03/2010 - 09/2006)|
|6.||Renwick, A G: 2 articles (05/2000 - 05/2000)|
|7.||Honeywell, R: 2 articles (05/2000 - 05/2000)|
|8.||Akinyinka, O O: 2 articles (05/2000 - 05/2000)|
|9.||Sowunmi, A: 2 articles (05/2000 - 05/2000)|
|10.||Baker, Arthur M: 1 article (10/2015)|
|2.||Disorders of Excessive Somnolence (Hypersomnia)
07/01/2010 - "Because it is also reported to provide neuroprotection, paraxanthine may be a better wake-promoting agent for hypersomnia associated with neurodegenerative diseases."
07/01/2010 - "We evaluated the wake-promoting efficacy of paraxanthine, caffeine, and a reference wake-promoting compound, modafinil, in a mice model of narcolepsy, a prototypical disease model of hypersomnia. "
09/28/2006 - "Furthermore, H2O2-induced necrosis could be prevented by a high dose of 1,7-dimethylxanthine. "
09/01/2006 - "For instance studies indicate that caffeine and its major metabolite paraxanthine suppress neutrophil and monocyte chemotaxis, and also suppress production of the pro-inflammatory cytokine tumour necrosis factor (TNF)-alpha from human blood. "
|4.||Liver Cirrhosis (Hepatic Cirrhosis)
02/01/2001 - "The aim of the study was to use the paraxanthine/caffeine ratio in saliva to evaluate liver function in patients with liver cirrhosis. "
02/01/2001 - "In patients with liver cirrhosis we found significantly lower paraxanthine/caffeine ratio which correlates with lowered elimination of caffeine. "
02/01/2001 - "[Use of the paraxanthine/caffeine ratio in the saliva of patients with liver cirrhosis]."
11/01/2011 - "Oral application of 1,7-dimethylxanthine (paraxanthine) attenuates the formation of experimental cholestatic liver fibrosis."
05/01/2000 - "Paraxanthine was the principal metabolite in all the three groups with Cmax significantly higher in healthy children (1.3 +/- 0.3 microg/ml) than in children with malaria (0.8 +/- 0.4 microg/ml) (P < 0.05) and kwashiorkor (0.3 +/- 0.1 microg/ml) (P < 0.0001). "
05/01/2000 - "The maximum plasma concentration (Cmax) of paraxanthine was significantly lower (P < 0.05) in malaria (0.9 +/- 0.4 microg/ ml) than in healthy controls (1.4 +/- 0.5 microg/ml), and the paraxanthine:caffeine area under the plasma concentration time curve ratio, an index of cytochrome P450 (CYP)IA2 activity was significantly lower (P < 0.05) in malaria patients (0.5 +/- 0.1) than in healthy controls (0.3 +/- 0.2). "
05/01/2000 - "CYP1A2 activity, measured by the plasma ratios of paraxanthine: caffeine, was significantly lower in kwashiorkor and malaria. "
12/01/1993 - "1. The effects of malaria infection due to Plasmodium berghei and Escherichia coli endotoxin-induced fever on the metabolism of orally-administered caffeine (CA: 10 mg/kg) to its primary metabolites (theobromine (TB), paraxanthine (PX) and theophylline (TH)) were studied in 5-week-old male Wistar rats (n = 5 for each treatment). "
|1.||Caffeine (No Doz)
|3.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|6.||Cytochrome P-450 CYP1A2 (CYP1A2)
|8.||Cytochrome P-450 Enzyme System (Cytochrome P450)